Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non Operating Income: 2018-2024

Historic Non Operating Income for Phathom Pharmaceuticals (PHAT) over the last 7 years, with Dec 2024 value amounting to -$56.9 million.

  • Phathom Pharmaceuticals' Non Operating Income rose 0.53% to -$14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.1 million, marking a year-over-year decrease of 18.55%. This contributed to the annual value of -$56.9 million for FY2024, which is 65.87% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Non Operating Income of -$56.9 million as of FY2024, which was down 65.87% from -$34.3 million recorded in FY2023.
  • Phathom Pharmaceuticals' Non Operating Income's 5-year high stood at -$3.4 million during FY2020, with a 5-year trough of -$56.9 million in FY2024.
  • Moreover, its 3-year median value for Non Operating Income was -$34.3 million (2023), whereas its average is -$38.8 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 97.71% in 2020, then slumped by 187.21% in 2022.
  • Yearly analysis of 5 years shows Phathom Pharmaceuticals' Non Operating Income stood at -$3.4 million in 2020, then tumbled by 158.68% to -$8.8 million in 2021, then slumped by 187.21% to -$25.3 million in 2022, then plummeted by 35.59% to -$34.3 million in 2023, then crashed by 65.87% to -$56.9 million in 2024.